Zymeworks Inc.
Zymeworks Inc.
- Market cap
- $1.81B
- P/E ratio
- 38.89
Your view on ZYME
Overview
What the company does, where it operates, and who runs it.
About Zymeworks Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kenneth H. Galbraith
- Headquarters
- 114 East 4th Avenue, Middletown, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Kenneth H. Galbraith
- Headquarters
- 114 East 4th Avenue, Middletown, BC, CA
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Zymeworks Inc.. Starting points for Zymeworks Inc.: P/E 38.9, EPS $0.60, beta 1.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Zymeworks Inc.. Trailing twelve-month EPS for Zymeworks Inc. stands at $0.60. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$42.11
average of 9 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy11
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.13 | −$0.14 | $1.27 | $0.69 |
| Low estimate | $0.06 | −$0.36 | $1.06 | −$2.08 |
| High estimate | $0.33 | $0.08 | $1.82 | $4.11 |
| No. of analysts | 6 | 2 | 7 | 8 |
| Year-ago EPS | −$0.55 | −$0.591 | −$1.081 | — |
| Growth | +122.9% | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $72.52M | $73.20M | $334.28M | $342.62M |
| Low estimate | $44.19M | $31.42M | $330.55M | $184.92M |
| High estimate | $86.40M | $114.97M | $338.71M | $528.90M |
| No. of analysts | 2 | 1 | 8 | 8 |
| Year-ago revenue | $2.52M | $2.41M | $105.97M | — |
| Growth | +2783.3% | +2939.8% | +215.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Zymeworks Inc.. Zymeworks Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ADCTADC Therapeutics S.A. | Healthcare | Biotechnology | $192.7M | ||
| ALXOALX Oncology Holdings Inc. | Healthcare | Biotechnology | $134.1M | ||
| CBIOCrescent Biopharma, Inc. | Healthcare | Biotechnology | $482.3M | ||
| CGENCompugen Ltd. | Healthcare | Biotechnology | $185.7M | ||
| CLDXCelldex Therapeutics, Inc. | Healthcare | Biotechnology | $2.2B | ||
| CTMXCytomX Therapeutics, Inc. | Healthcare | Biotechnology | $409.8M | ||
| IMNMImmunome, Inc. | Healthcare | Biotechnology | $2.0B | ||
| MGNXMacroGenics, Inc. | Healthcare | Biotechnology | $125.9M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| XRTX.VXORTX Therapeutics Inc. | Healthcare | TSXV | — | ||
| XSNXNovAccess Global Inc. | Healthcare | OTC | $6,165 | ||
| XTLBXTL Biopharmaceuticals Ltd. | Healthcare | NASDAQ | $1.5M | ||
| YARWYarrow Bioscience Inc | Healthcare | NASDAQ | $135.4M | ||
| YDESYD Bio Limited Ordinary Shares | Healthcare | NASDAQ | $343.5M | ||
| YDESWYD Bio Limited Warrants | Healthcare | NASDAQ | $1.4M | ||
| YECOYulong Eco-Materials Limited | Healthcare | OTC | $592,481 | ||
| ZBIOZenas BioPharma, Inc. | Healthcare | NASDAQ | $1.8B | ||
| ZEOXZeo ScientifiX, Inc. | Healthcare | OTC | $15.4M | ||
| ZHCLFZenith Capital Corp. | Healthcare | OTC | $15.9M | ||
| ZIVOZIVO Bioscience, Inc. | Healthcare | OTC | $36.4M | ||
| ZLABZai Lab Limited | Healthcare | NASDAQ | $2.5B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged) | $627M in assets | 0.04% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.04% | |
| IBBiShares Biotechnology ETF | $11.1B in assets | 0.13% | |
| BBPVirtus LifeSci Biotech Products ETF | $133M in assets | 1.57% | |
| CANCTema Oncology ETF | $215M in assets | 1.21% | |
| DWASInvesco Dorsey Wright SmallCap Momentum ETF | $376M in assets | 0.41% | |
| FSMLFranklin Small Cap Enhanced ETF | $146M in assets | 0.36% | |
Largest holders first, then the funds most concentrated in ZYME.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Zymeworks Inc., and how their positions are changing. At a $1.81B market value, institutional positions materially move Zymeworks Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Zymeworks Inc. executives and directors. Shares of Zymeworks Inc. have traded between $9.03 and $26.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Zymeworks Inc.. Coverage tracks Zymeworks Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Zymeworks Inc.